Puig Aims to Double Uriage Sales and Build a €1bn Dermocosmetics Arm

Puig has committed to doubling the sales of its French dermocosmetic brand Uriage by 2032, part of a plan to become what CEO Jose Manuel Albesa calls a "global dermocosmetics champion."

Albesa laid out the strategy at the company's Capital Markets Day 2026 in Madrid on 28 October. The event set Puig's priorities for its next phase of growth, and dermocosmetics sat at the center of them.

"We want to be a global dermocosmetics champion," Albesa said, framing the category as a core pillar of Puig's future rather than a side business.

The ambitions are large. Puig wants to exceed €8bn in annual net revenues by 2032 and to break into the ranks of the top four premium beauty companies worldwide. Dermocosmetics, alongside its established fragrance and make-up operations, is expected to carry much of that growth.

How will Uriage double in size?

The Uriage growth plan rests on three levers. First, expansion into higher-value product categories. Second, a stronger presence in Europe and Latin America. Third, an accelerated e-commerce push and what the company calls "deeper partnerships" with major pharmacy and para-pharmacy groups.

The pharmacy channel matters here. Dermocosmetics brands traditionally live behind the pharmacy counter, and tighter integration with those retail networks is a proven route to volume. Puig also said it will expand all its dermocosmetics brands "into new markets and channels, including specialist beauty, department stores, travel retail and digital platforms," according to a company statement.

Marc Toulemonde, Puig's President, Derma, said the goal is to transform Uriage from "a regional champion into a global dermocosmetics leader." That wording signals the brand's current footprint: strong in European pharmacy retail, thinner elsewhere.

In plain terms, Puig wants Uriage selling twice as much, in more countries, through more channels, within about seven years.

What does the Isdin acquisition add?

The boldest move is the pending full acquisition of skin care brand Isdin. Puig has agreed to buy out Corporación Químico-Farmacéutica Esteve's (CQFE) stake and take complete ownership.

Isdin generated roughly €650m in revenues in 2025. That figure alone would make it one of the largest assets in Puig's dermocosmetics portfolio. The deal is expected to close in Q1 2027, subject to regulatory approvals.

Once complete, Isdin will become a key pillar in Puig's dermocosmetics platform. Combined with Uriage and Apivita, the Greek natural skin and hair care brand, the platform would command more than €1bn in pro forma net revenues.

For context, that means Puig's derma division alone would rival mid-sized standalone beauty companies. It also gives the Barcelona-based group three brands with distinct geographic strengths — Isdin in Spain and Latin America, Uriage in European pharmacy, Apivita in natural care — that can be cross-expanded into each other's markets.

How big is the market Puig is chasing?

The underlying market numbers explain the urgency. The global dermocosmetics market was valued at US$47.9bn in 2025 and is projected to reach $117bn by 2034, according to analyst Fortune Business Insights.

That is more than a doubling in nine years — a growth rate most beauty segments cannot match. Dermocosmetics, which sit at the intersection of pharmacy credibility and consumer skincare demand, have benefited from consumers seeking clinically positioned products.

Puig's interest in the category is not new. The company reported record Q3 revenue of €1.4bn, driven by its fragrance and make-up brands, and it has been steadily deepening its "presence in dermocosmetics" through acquisitions and investment.

The strategic logic is straightforward: fragrances remain Puig's engine, but dermocosmetics offer the next durable growth curve, with pharmacy channel trust that pure-play beauty brands struggle to replicate.

What comes next?

The timeline is now fixed. Isdin's regulatory approvals must clear before Q1 2027. Uriage's doubling target runs to 2032, the same year Puig aims to pass €8bn in net revenues and secure a top-four position in premium beauty.

Between now and then, the test will be execution: integrating Isdin, scaling Uriage beyond its regional strongholds, and expanding Apivita — all while the dermocosmetics market's projected climb toward $117bn draws competitors toward the same shelf space.

If Albesa's plan holds, Puig will arrive in 2032 with a dermocosmetics platform worth more than €1bn and a claim to the category's global leadership.